000 | 02431cam a2200181 4500 | ||
---|---|---|---|
001 | NMDX7841 | ||
008 | 120401t2015 xxu||||| |||| 00| 0 eng d | ||
100 | _aAinsworth, J. | ||
240 | _aEBioMedicine | ||
245 | _aDuring stably suppressive antiretroviral therapy integrated HIV-1 DNA load in peripheral blood is associated with the frequency of CD8 cells expressing HLA-DR/DP/DQ | ||
260 | _c2015 | ||
500 | _aNMUH Staff Publications | ||
500 | _aEMBASE | ||
500 | _a2 | ||
520 | _a<span style="font-size: 10pt;">Background: Characterising the correlates of HIV persistence improves understanding of disease pathogenesis and guides the design of curative strategies. This study investigated factors associated with integrated HIV-1 DNA load during consistently suppressive first-line antiretroviral therapy (ART). Method: Total, integrated, and 2-long terminal repeats (LTR) circular HIV-1 DNA, residual plasma HIV-1 RNA, T-cell activation markers, and soluble CD14 (sCD14) were measured in peripheral blood of 50 patients that had received 1-14. years of efavirenz-based or nevirapine-based therapy. Results: Integrated HIV-1 DNA load (per 106 peripheral blood mononuclear cells) was median 1.9 log10 copies (interquartile range 1.7-2.2) and showed a mean difference of 0.2 log10 copies per 10years of suppressive ART (95% confidence interval -0.2, 0.6; p=0.28). It was positively correlated with total HIV-1 DNA load and frequency of CD8+HLA-DR/DP/DQ+ cells, and was also higher in subjects with higher sCD14 levels, but showed no correlation with levels of 2-LTR circular HIV-1 DNA and residual plasma HIV-1 RNA, or the frequency of CD4+CD38+ and CD8+CD38+ cells. Adjusting for pre-ART viral load, duration of suppressive ART, CD4 cell counts, residual plasma HIV-1 RNA levels, and sCD14 levels, integrated HIV-1 DNA load was mean 0.5 log10 copies higher for each 50% higher frequency of CD8+HLA-DR/DP/DQ+ cells (95% confidence interval 0.2, 0.9; p=0.01). Conclusions: The observed positive association between integrated HIV-1 DNA load and frequency of CD8+DR/DP/DQ+ cells indicates that a close correlation between HIV persistence and immune activation continues during consistently suppressive therapy. The inducers of the distinct activation profile warrant further investigation.&nbsp;</span> | ||
700 | _aWaters, A. | ||
856 | _uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588402/pdf/main.pdf | ||
999 |
_c76614 _d76614 |